Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed Or Refractory Multiple Myeloma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Active Not RecruitingNCT05405166
What this trial is testing

SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM

Who this might be right for
Plasma Cell Myeloma Recurrent
Sanofi 531
Testing effectiveness (Phase 2)Ended earlyNCT00412919
What this trial is testing

Study of Azacitidine to Treat Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Bayside Health 7
Early research (Phase 1)Active Not RecruitingNCT03091257
What this trial is testing

Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Massachusetts General Hospital 30
Early research (Phase 1)Ended earlyNCT03031730
What this trial is testing

Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma

Who this might be right for
PlasmacytomaRecurrent Multiple MyelomaRefractory Multiple Myeloma
National Cancer Institute (NCI) 35
Testing effectiveness (Phase 2)WithdrawnNCT00112879
What this trial is testing

Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Treating Patients With Multiple Myeloma

Who this might be right for
Stage I Multiple MyelomaStage II Multiple MyelomaStage III Multiple Myeloma+1 more
The Cleveland Clinic
Early research (Phase 1)UnknownNCT03751293
What this trial is testing

BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma

Who this might be right for
Relapsed or Refractory Multiple Myeloma
Hebei Yanda Ludaopei Hospital 10
Not applicableStudy completedNCT03433001
What this trial is testing

A Study in Relapsed and/or Refractory Multiple Myeloma Patients Treated With Ixazomib Plus Lenalidomide and Dexamethasone

Who this might be right for
Relapsed and/or Refractory Multiple Myeloma
Takeda 295
Testing effectiveness (Phase 2)Study completedNCT02902965
What this trial is testing

Study of Ibrutinib in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed/Relapsed and Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Pharmacyclics Switzerland GmbH 74
Testing effectiveness (Phase 2)Study completedNCT00079456
What this trial is testing

Temsirolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Refractory Multiple MyelomaStage I Multiple MyelomaStage II Multiple Myeloma+1 more
National Cancer Institute (NCI) 25
Early research (Phase 1)Active Not RecruitingNCT03145181
What this trial is testing

Dose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Hematological Malignancies
Janssen Research & Development, LLC 302
Early research (Phase 1)UnknownNCT05020639
What this trial is testing

TQB3820 in Patients With Hematological Malignancies

Who this might be right for
Hematological Malignancies
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 116
Not applicableNo Longer AvailableNCT02856438
What this trial is testing

Early Patient Access Treatment Use Protocol CA204-220

Who this might be right for
Multiple Myeloma
Bristol-Myers Squibb
Early research (Phase 1)Study completedNCT03242889
What this trial is testing

Subcutaneous Delivery of JNJ-54767414 (Daratumumab) in Japanese Participants With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Janssen Pharmaceutical K.K. 6
Early research (Phase 1)UnknownNCT00769613
What this trial is testing

Emergency Use of Donor Lymphocytes in Treating Patients Who Have Undergone Donor Stem Cell Transplant and Have Cytomegalovirus Infections

Who this might be right for
Cancer
Milton S. Hershey Medical Center 20
Early research (Phase 1)Study completedNCT00398515
What this trial is testing

Lenalidomide and Temsirolimus in Treating Patients With Previously Treated Multiple Myeloma

Who this might be right for
Refractory Multiple MyelomaStage II Multiple MyelomaStage III Multiple Myeloma
National Cancer Institute (NCI) 25
Testing effectiveness (Phase 2)Looking for participantsNCT06083207
What this trial is testing

IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Innovent Biologics (Suzhou) Co. Ltd. 116
Early research (Phase 1)Ended earlyNCT03266692
What this trial is testing

Study of ACTR087 in Combination With SEA-BCMA in Subjects With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple MyelomaMultiple Myeloma in RelapseRefractory Multiple Myeloma
Cogent Biosciences, Inc. 15
Early research (Phase 1)Study completedNCT00806065
What this trial is testing

Study of ENMD-2076 in Patients With Multiple Myeloma

Who this might be right for
Multiple Myeloma
CASI pharmaceuticals, Inc. 13
Testing effectiveness (Phase 2)WithdrawnNCT01647165
What this trial is testing

Phase II Study of Subcutaneous (SC) Bortezomib, Lenalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma; Followed by SC Bortezomib Maintenance

Who this might be right for
Multiple Myeloma
National Cancer Institute (NCI)
Testing effectiveness (Phase 2)Study completedNCT01989598
What this trial is testing

Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Recurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma
National Cancer Institute (NCI) 25
Next Page